亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Prospective Analysis of Arteriovenous Fistula Performance in the Context of Competing Risks

医学 背景(考古学) 动静脉瘘 血液透析 观察研究 前瞻性队列研究 外科 内科学 古生物学 生物
作者
Anukul Ghimire,Anita Lloyd,Susan K. Szigety,José Luis Merino,Karim Alibhai,Gerrit B. Winkelaar,Robert R. Quinn,Marcello Tonelli
出处
期刊:Kidney360 [American Society of Nephrology (ASN)]
标识
DOI:10.34067/kid.0000000650
摘要

Background: Many patients with newly created arteriovenous fistulas (AVF) may die before the AVF is needed for hemodialysis. However, formal competing risks frameworks are rarely used to report AVF patency, which may lead to biased estimates. We sought to identify the proportion of newly created AVF experiencing primary non-function and to describe long-term patency using a competing risk framework. Methods: We did a prospective observational study in 257 adults with newly created AVF in Alberta, Canada. The primary outcome was primary non-function. Secondary outcomes included loss of primary-patency, loss of assisted primary-patency, and loss of secondary functional-patency. Results were presented using icon-array plots to form the basis for future decision aids. Results: Participants were 63.0% male with mean age 62.3 years and median follow-up of 18.5 months (range 0.02-180 months). Of 257 participants, 50 could not be assessed for function or primary non-function, usually due to death. Of the remaining 207, 102 (49.3%) had primary non-function, and function was ultimately established for 142 (68.6%). Thus, only 142 of the 257 participants (55.3%) ultimately used the AVF for hemodialysis. High rates of competing risks led to biased results from Kaplan-Meier analyses of lost patency. When accounting for competing risks, loss of primary-patency among AVF with established function was 36.6%, 65.5% and 66.2%, at 1y, 3y and 5y respectively. Conclusions: Only 55% of fistulas were ultimately used for hemodialysis when accounting for competing risks and primary non-function. These results and the icon-array plots may inform discussions surrounding vascular access options for patients.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
忐忑的烤鸡完成签到,获得积分10
2秒前
5秒前
慕青应助Lance采纳,获得30
6秒前
Enso完成签到,获得积分10
7秒前
moiumuio完成签到 ,获得积分0
8秒前
Enso发布了新的文献求助10
10秒前
幽默的季节完成签到 ,获得积分10
18秒前
Lance关注了科研通微信公众号
25秒前
科目三应助Enso采纳,获得30
25秒前
有只kangaroo完成签到 ,获得积分10
26秒前
我爱学习完成签到 ,获得积分10
28秒前
忧伤的绍辉完成签到,获得积分10
29秒前
Criminology34应助科研通管家采纳,获得10
30秒前
共享精神应助科研通管家采纳,获得10
30秒前
Lucas应助科研通管家采纳,获得10
30秒前
Criminology34应助科研通管家采纳,获得10
31秒前
科研通AI6应助科研通管家采纳,获得10
31秒前
39秒前
章鱼完成签到,获得积分10
40秒前
活泼醉冬发布了新的文献求助10
43秒前
lvlv完成签到,获得积分10
50秒前
51秒前
SSS发布了新的文献求助10
56秒前
Lance完成签到,获得积分20
57秒前
djnjv完成签到 ,获得积分10
1分钟前
11完成签到 ,获得积分10
1分钟前
001完成签到 ,获得积分0
1分钟前
艾卡西亚毛毛雨完成签到 ,获得积分10
1分钟前
stone完成签到 ,获得积分10
1分钟前
清飏给Jack80的求助进行了留言
1分钟前
11112321321完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
爆米花应助YOKO采纳,获得30
1分钟前
1分钟前
重重发布了新的文献求助10
1分钟前
Dannnn完成签到 ,获得积分10
1分钟前
激流勇进wb完成签到 ,获得积分10
1分钟前
1分钟前
清飏应助Jack80采纳,获得200
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Basic And Clinical Science Course 2025-2026 3000
《药学类医疗服务价格项目立项指南(征求意见稿)》 880
花の香りの秘密―遺伝子情報から機能性まで 800
3rd Edition Group Dynamics in Exercise and Sport Psychology New Perspectives Edited By Mark R. Beauchamp, Mark Eys Copyright 2025 600
1st Edition Sports Rehabilitation and Training Multidisciplinary Perspectives By Richard Moss, Adam Gledhill 600
nephSAP® Nephrology Self-Assessment Program - Hypertension The American Society of Nephrology 550
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5622185
求助须知:如何正确求助?哪些是违规求助? 4707074
关于积分的说明 14938561
捐赠科研通 4768447
什么是DOI,文献DOI怎么找? 2552156
邀请新用户注册赠送积分活动 1514317
关于科研通互助平台的介绍 1475005